Revolution Medicines threatens lawsuit against Erasca over RAS drug patent and efficacy claims

Earlier this month a newly announced cancer therapy generated strong interest from patients and investors. The drug, which targets the RAS pathway, was highlighted for its potential impact on oncology treatment.

Erasca disclosed that Revolution Medicines has sent a legal threat, alleging that Erasca’s RAS drug infringes on patents and does not meet efficacy standards claimed by Revolution. The biotech said the threat could lead to a lawsuit if the issues are not resolved.

The confrontation introduces regulatory and commercial risk for both companies and adds uncertainty for investors tracking the RAS drug space.